Results 191 to 200 of about 318,699 (248)

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

Efficacy and Acceptability of Thermal Ablation in Patients with Positive Documented Visual Inspection with Acetic Acid (Do-VIA) Results. [PDF]

Int J Womens Health
Azizah S, Purwoto G, Nuranna L, Anggraeni TD, Utami TW, Fahrunnisa F, Firdaus ND.   +6 more
europepmc   +1 more source

Survivin and Aurora Kinase A control cell fate decisions during mitosis

Molecular Oncology, EarlyView.
Aurora A interacts with survivin during mitosis and regulates its centromeric role. Loss of Aurora A activity mislocalises survivin, the CPC and BubR1, leading to disruption of the spindle checkpoint and triggering premature mitotic exit, which we refer to as ‘mitotic slippage’.
Hana Abdelkabir, Shalitha Wickrama Arachchige, Sally P. Wheatley   +2 more
wiley   +1 more source

Apparent Diffusion Coefficient as a Predictor of Microwave Ablation Response in Thyroid Nodules: A Prospective Study. [PDF]

Diagnostics (Basel)
Demir M, Yasar Y.
europepmc   +1 more source

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source

Comparison of chemical treatments to ablate the lateral line system in two freshwater fishes, bumblebee goby <i>Brachygobius doriae</i> and silver hatchetfish <i>Gasteropelecus</i> sp. [PDF]

MicroPubl Biol
Kapoor H, Levin J, Azevedo A, Chhetri S, Lassen K, Zheng J, Schwalbe MAB.   +6 more
europepmc   +1 more source

The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategies

Molecular Oncology, EarlyView.
RAS‐targeted therapies have become a clinical reality. Although promising results in patients have been achieved, there are still challenges ahead such as coping with drug resistance. Here we summarize selected RAS inhibitors targeting either individual KRAS mutant isoforms (KRASG12C, KRASG12D, KRASG12V) or exhibiting a wider inhibitory spectrum ...
Matthias Drosten, Mariano Barbacid
wiley   +1 more source

Fine-tuning the arc of orbital atherectomy: navigating eccentric calcium in tortuous vessels. [PDF]

AsiaIntervention
Abu-Much A, Kirtane AJ.
europepmc   +1 more source

A guide to reactive oxygen species in tumour hypoxia: measurement and therapeutic implications

Molecular Oncology, EarlyView.
Hypoxia reshapes tumour redox landscapes by altering compartmental ROS production (mitochondria, NOX, ER, peroxisomes). Accurate interpretation requires oxygen‐contextualised measurement (live biosensors, chemical probes, EPR, LC–MS) and awareness of artefacts (reoxygenation, probe specificity).
Lina Hacker, Elysia Sarsam, Stuart J. Conway, Ester M. Hammond   +3 more
wiley   +1 more source

Safety and effectiveness of catheter ablation of atrial fibrillation in patients with mitral valve replacement mechanical versus bioprosthetic valves. [PDF]

Sci Rep
Liu XY, Long DY, Dong JZ, Du X, Sang CH, Yu RH, Jiang CX, Liu N, Li SN, Wang W, Guo XY, Zhao X, Li CY, Zuo S, Li MM, Jia CQ, Jiang YX, Lv WH, Wu ZY, Li YK, Wang XS, Du ZH, Tang RB, Ma CS.   +23 more
europepmc   +1 more source